CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin GrowthZacks Investment Research · Sep 15, 2026
Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call TranscriptSeeking Alpha · Sep 10, 2026
Champions Oncology Q1 Earnings Call HighlightsMarketBeat · Sep 10, 2026
Champions Oncology Reports Revenue of $15.2 MillionAccesswire · Sep 10, 2026
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI PushZacks Investment Research · Jul 30, 2026
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call TranscriptSeeking Alpha · Jul 27, 2026Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 10, 2026 | -$0.01 | $0.05 | Beat |
| Jul 27, 2026 | -$0.05 | $0.01 | Beat |
| Mar 12, 2026 | $0.09 | -$0.02 | Miss |
| Dec 15, 2025 | $0.08 | $0.02 | Miss |
| Sep 15, 2025 | -$0.01 | -$0.03 | Miss |
| Jul 23, 2025 | -$0.20 | -$0.13 | Beat |